ReviewTrends in parasitology2019
Evaluating the Evidence for Lymphatic Filariasis Elimination.
Review in Trends in parasitology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A next-generation human lymphatic filariasis vaccine candidate, rBmHAXT, for clinical development.NPJ vaccines · 2026Article
- Impact of mass drug administration with Ivermectin, Diethylcarbamazine, and Albendazole in elimination of lymphatic filariasis in five districts of Nepal.PLOS global public health · 2026Article
- The effects of variable spatial aggregation on lymphatic filariasis transmission.Parasites & vectors · 2025Article
- Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- How correlations between treatment access and surveillance inclusion impact neglected tropical disease monitoring and evaluation-A simulated study.PLoS neglected tropical diseases · 2023Article
- Artificial intelligence and lymphedema: State of the art.Journal of clinical and translational research · 2022Review
- What Can Modeling Tell Us About Sustainable End Points for Neglected Tropical Diseases?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Loop-Mediated Isothermal Amplification as Point-of-Care Diagnosis for Neglected Parasitic Infections.International journal of molecular sciences · 2020Review
- Defining a prevalence level to describe the elimination of Lymphatic Filariasis (LF) transmission and designing monitoring & evaluating (M&E) programmes post the cessation of mass drug administration (MDA).PLoS neglected tropical diseases · 2020Article
- Elimination or Resurgence: Modelling Lymphatic Filariasis After Reaching the 1% Microfilaremia Prevalence Threshold.The Journal of infectious diseases · 2020Article
- Advances in Vaccine Development for Human Lymphatic Filariasis.Trends in parasitology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the global drive for elimination of lymphatic filariasis (LF), 15 countries have achieved validation of elimination as a public health problem (EPHP). Recent empirical evidence has demonstrated that EPHP does not always lead to elimination of transmission (EOT). Here we show how the probability of elimination explicitly depends on key biological parameters, many of which have been poorly characterized, leading to a poor evidence base for the elimination threshold. As more countries progress towards EPHP it is essential that this process is well-informed, as prematurely halting treatment and surveillance programs could pose a serious threat to global progress. We highlight that refinement of the weak empirical evidence base is vital to understand drivers of elimination and inform long-term policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.